MOv19-BBz CAR T cells

BIOLOGICAL2 trials

Sponsors

University of Pennsylvania

Conditions

Fallopian Tube CancerMetastatic Non Small Cell Lung CancerOvarian CancerPrimary Peritoneal CarcinomaRecurrent Lung Non-Small Cell Carcinoma

Phase 1

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT03585764

University of PennsylvaniaFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2018-10-24End: 2024-03-26Updated: 2025-03-26

MOv19-BBz CAR T Cells in FRa+ Cancers

RecruitingNCT07116057

University of PennsylvaniaMetastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma

Start: 2025-10-07End: 2040-10-01Target: 10Updated: 2026-06-18

Related Papers

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

2026-05-01

431 First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer

Regular and Young Investigator Award Abstracts2021-11-017 citations